Investigational drug · Phase 3
VC004
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Locally Advanced Solid Tumor.
Phase 3Last checked: Nov 19, 2026Latest source record: Jul 27, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
6
Any phase or sponsor naming "VC004"
First trial start
2025
Mar 17, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "VC004", any sponsor or status.
Conditions studied
As listed on its trial records.
- Locally Advanced Solid Tumor
Approved drugs for the same conditions: Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "VC004" as an intervention, largest first.
- The Phase I/Phase II Clinical Study of VC004 in Patients With Localized Advanced/Metastatic Solid TumorsStatus unknown
Jiangsu vcare pharmaceutical technology co., LTDIndustry
NCT04614740 · 115 participants (planned) · Start Nov 20, 2020 · Primary completion Jan 31, 2024
Drug: VC004 · For: Locally Advanced Solid Tumor; Metastatic Solid Tumor
Sites: Hefei, China; Chongqing, China; Fuzhou, China · 21 sites in all
Jiangsu vcare pharmaceutical technology co., LTDIndustry
NCT06529445 · 84 participants · Start Jul 22, 2024 · Primary completion Aug 26, 2024
Drug: High Dose VC004 Capsules; Median Dose VC004 Capsules and 1 more · For: Locally Advanced or Metastatic Solid Tumor Harboring an NTRK Gene Fusion
Sites: Nanjing, China
Jiangsu vcare pharmaceutical technology co., LTDIndustry
NCT06619951 · 56 participants · Start Sep 18, 2024 · Primary completion Oct 31, 2024
Drug: VC004 and Itraconazole; VC004 and rifampicin · For: Locally Advanced or Metastatic Solid Tumor
Sites: Nanjing, China
- Phase III Clinical Study of VC004 in Patients With Localized Advanced/ Metastatic Solid TumorsPivotal-lookingRecruiting
Jiangsu vcare pharmaceutical technology co., LTDIndustry
NCT06658353 · 54 participants (planned) · Start Mar 17, 2025 · Primary completion Dec 30, 2026
Drug: VC004 Capsules · For: Locally Advanced Solid Tumor
Sites: Beijing, China
- A Phase Ib, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of VC004 Capsules for Pain in Bone MetastasesNot yet recruiting
Jiangsu vcare pharmaceutical technology co., LTDIndustry
NCT07731685 · 26 participants (planned) · Start Jul 30, 2026 · Primary completion Dec 30, 2027
Drug: VC004 low dose; VC004 high dose and 1 more · For: Pain in Bone Metastases
Sites: Nanjing, China · 2 sites in all
Jiangsu vcare pharmaceutical technology co., LTDIndustry
NCT05528120 · 16 participants · Start Oct 20, 2022 · Primary completion Oct 28, 2022
Drug: VC004 Capsules; VC004 Capsules · For: Locally Advanced or Metastatic Solid Tumor Harboring an NTRK Gene Fusion
Sites: Nanjing, China
Newest research
PubMed records naming it or its code names, newest first.
- Safety, efficacy, and pharmacokinetics of eratrectinib (VC004) in solid tumors with NTRK fusions: phase 1 results from a phase 1/2 study.
Zhou S, Zhang C, Wang G, et al. · Exp Hematol Oncol 2026
- ETV6::NTRK3 gene fusion in a patient with metastatic lung atypical carcinoid successfully treated with repotrectinib: A case report.
Gao L, Ai X, Lu S · Lung Cancer 2024
- Food Effect on the Pharmacokinetics of VC004, a Tropomyosin Receptor Kinase Inhibitor: A Randomized Crossover Trial in Healthy Chinese Subjects.
Hu L, Sun Q, Tang L, et al. · Clin Drug Investig 2024
- Preclinical testing of N-[(11)c]-methyl-piperidin-4-yl 2-cyclohexyl-2-hydroxy-2-phenylacetate, a novel radioligand for detection of cerebral muscarinic receptors using PET.
Visser TJ, Van Waarde A, Doze P, et al. · Synapse 2000
Also in development for Locally Advanced Solid Tumor
- NeladalkibNVL-655Phase 32 trials
Nuvalent Inc. · Non-small Cell Lung Cancer, Anaplastic Lymphoma Kinase-positive, Locally Advanced Solid Tumor
- TNG462Phase 23 trials
Tango Therapeutics, Inc. · MTAP-deleted Solid Tumors, Locally Advanced Solid Tumor, PDAC
- FMC-376Phase 22 trials
Frontier Medicines Corporation · Advanced Solid Tumors With KRAS G12C Mutations, Solid Tumor, Adult, Unresectable Solid Tumor
- FMC-242Phase 21 trial
Frontier Medicines Corporation · Locally Advanced Solid Tumor
- FOG-001Phase 21 trial
Parabilis Medicines, Inc. · Cancer, Colorectal Cancer, Solid Tumor
- IPN60300Phase 21 trial
Ipsen · Locally Advanced Solid Tumor, Metastatic Solid Tumor
- TST003Phase 21 trial
Transcenta Therapeutics (Hangzhou) Co., Ltd. · Locally Advanced Solid Tumor, Metastatic Tumor, Colorectal Adenocarcinoma
- YH32364Phase 21 trial
Yuhan Corporation · EGFR Overexpression, Locally Advanced Solid Tumor, Metastatic Solid Tumor
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.